^
Association details:
| Biomarker: | FANCD2 mutation + EP300 mutation |
|---|---|
| Cancer: | Squamous Cell Carcinoma of Head and Neck |
| Drug: | buparlisib (AN2025) (PI3K inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A phase I study of the PI3K inhibitor buplarlisib (B) with concurrent chemoradiotherapy (CRT) in patients with high risk locally advanced squamous cell cancer of the head and neck (LASCCHN). Add to Collection
Excerpt:
In this phase I study, the oral pan-PI3K inhibitor B combined with CRT was tested in pts with stage III/IV LASCCHN...4/5 cases with response to B alone had sequencing results and demonstrated mutations in FANCD2/EP300; FANCA/FGFR3; FANCI/FLT1 and PIC3CA/EP300.
Secondary therapy:
cisplatin
DOI:
10.1200/JCO.2018.36.15_suppl.6071
Trial ID:
